Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Calendar
Screener
News
About

CBIO - Crescent Biopharma, Inc. Financial... | Finranks

Home

/

CBIO

C

Crescent Biopharma, Inc. (CBIO)

NCM – Real Time Price. Currency in USD

16.43

-0.26 (-1.56%)

Market open: Aug 12, 2026, 11:31 AM EDT

16.69

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Total Assets

Total Liabilities

Stockholders Equity

Total Debt

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

11M

0

10K

75K

Cost of goods sold

-84K

0

-153K

-1M

Gross Profit

11M

0

-143K

-957K

Operating expenses (excl. COGS)

-163M

-17M

-39M

-46M

Operating Income

-153M

-17M

-39M

-47M

Non-operating income, total

690K

-676K

2M

715K

Pretax income

-152M

-18M

-37M

-47M

Equity in earnings

0

0

0

0

Taxes

-2M

0

0

0

Non-controlling/minority interest

0

0

0

0

After tax other income/expense

0

0

0

0

Net income before discontinued operations

-154M

-18M

-37M

-47M

Discontinued operations

0

0

0

0

Net income

-154M

-18M

-37M

-47M

Dilution adjustment

0

0

0

0

Preferred dividends

-

0

0

0

Name

2025

2024

2023

2022

Total assets

240M+574.7%

36M-21.4%

45M-12.5%

52M

Total current assets

237M

35M

44M

51M

Total non-current assets

4M

813K

2M

1M

Total liabilities

37M-27.0%

51M+640.3%

7M-22.3%

9M

Total current liabilities

36M

10M

7M

9M

Total non-current liabilities

1M

41M

67K

0

Total equity

203M

-15M

38M

43M

Total liabilities & shareholders' equities

240M

36M

45M

52M

Total debt

2M-96.0%

41M+5031.4%

808K-12.0%

919K

Name

2025

2024

2023

2022

Cash from operating activities

-72M

-6M

-35M

-46M

Cash from investing activities

-73M

0

-21K

-84K

Cash from financing activities

323M

41M

29M

4M

Free cash flow

-72M-1055.7%

-6M+82.0%

-35M+25.0%

-47M